Results 311 to 320 of about 3,169,653 (411)

Design of an innovative nanovehicle to enhance brain permeability of a novel 5-HT6 receptor antagonist. [PDF]

Int J Pharm X
Alvarez-Figueroa MJ, Nuñez-Navarro F, Recabarren-Gajardo G, González-Aramundiz JV.   +3 more
europepmc   +1 more source

Patient Perceptions of Medication Therapy for Prevention of Posttraumatic Osteoarthritis Following Anterior Cruciate Ligament Injury: A Qualitative Content Analysis

Arthritis Care &Research, EarlyView.
Objective Posttraumatic osteoarthritis (PTOA) accounts for nearly 12% of osteoarthritis incidences and often occurs after anterior cruciate ligament (ACL) tear. Ensuring the uptake of preventive treatments for PTOA requires that investigators and clinicians understand factors influencing patients to seek preventive therapies.
Lily M. Waddell, Donald P. Mitchener, Kelly C. Frier, Morgan H. Jones, Elena Losina, Nick Bansback, Liana Fraenkel, Jason S. Kim, Jeffrey N. Katz, Faith Selzer, Adam Easterbrook   +10 more
wiley   +1 more source

Association Between Metabolic Syndrome and Radiographic Changes in Psoriatic Arthritis: A Cohort Study

Arthritis Care &Research, EarlyView.
Objective Metabolic syndrome (MetS) is a known comorbidity of psoriatic arthritis (PsA) and is associated with PsA disease activity. We aimed to explore the association between MetS and radiographic features (peripheral and axial) in PsA. Methods We included patients with PsA followed at our prospective observational cohort for the period between 1978 ...
Fadi Kharouf, Shangyi Gao, S. Ercan Tunc, Justine Y. Ye, Daniel Pereira, Dafna D. Gladman, Vinod Chandran   +6 more
wiley   +1 more source

IL-1 Receptor Antagonist Anakinra Inhibits the Effect of IL-1β- Mediated Osteoclast Formation by Periodontal Ligament Fibroblasts. [PDF]

Biology (Basel)
Steemers E, Talbi WMI, Hogervorst JMA, Schoenmaker T, de Vries TJ.   +4 more
europepmc   +1 more source

Metabolic Consequences of Rheumatoid Arthritis

Arthritis Care &Research, EarlyView.
Patients with rheumatoid arthritis (RA) may have metabolic disruption, which can contribute to adverse long‐term outcomes, for multiple reasons. Patients with RA appear to have a higher risk of sarcopenia, type 1 and type 2 diabetes mellitus, metabolic syndrome, and hypertension. Systemic inflammation in RA can cause a “lipid paradox,” with reduced low‐
Stevie Barry, Emily Sheng, Joshua F. Baker   +2 more
wiley   +1 more source

Glucagon Receptor Antagonist for Heart Failure With Preserved Ejection Fraction. [PDF]

Circ Res
Gao C, Xiong Z, Liu Y, Wang M, Wang M, Liu T, Liu J, Ren S, Cao N, Yan H, Drucker DJ, Rau CD, Yokota T, Huang J, Wang Y.   +14 more
europepmc   +1 more source

Risk of Hepatotoxicity in Patients With Gout Treated With Febuxostat or Benzbromarone: A Propensity Score–Matched Cohort Study

Arthritis Care &Research, EarlyView.
Objective The objective of this study was to evaluate and compare the risk of hepatotoxicity associated with the use of febuxostat and benzbromarone in patients with gout. Methods New users of febuxostat or benzbromarone with monitoring of liver function at least three times in a year after initiation of the study drugs were identified from an ...
Wenyan Sun, Lingling Cui, Robert Terkeltaub, Ying Chen, Xinde Li, Xiaoyu Cheng, Tian Liu, Nicola Dalbeth, Changgui Li   +8 more
wiley   +1 more source

Navacaprant, a Novel and Highly Selective Kappa Opioid Receptor Antagonist, in Adults With Major Depressive Disorder: A Randomized, Double-Blind Phase 2 Clinical Trial. [PDF]

J Clin Psychopharmacol
Mathew SJ, Cutler AJ, Visitacion NC, Gold M, Yuan J, Aurora B.   +5 more
europepmc   +1 more source

Colchicine Concentrations and Relationship With Colchicine Efficacy and Adverse Events: Post Hoc Analysis of a Randomized Clinical Trial of Colchicine for Gout Flare Prophylaxis

Arthritis Care &Research, EarlyView.
Objective Our objective was to examine the relationship between colchicine plasma concentrations and clinical and demographic factors and to determine the relationship between colchicine concentrations and colchicine efficacy and colchicine‐specific adverse events.
Lisa K. Stamp, Anne Horne, Borislav Mihov, Jill Drake, Janine Haslett, Peter Chapman, Daniel F. B. Wright, Christopher Frampton, Nicola Dalbeth   +8 more
wiley   +1 more source